The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI).

• DOI: 10.1200/jco.2011.29.15_suppl.7517
• Publication Date: 2017-02-23T18:58:03Z
• Authors: T. M. Ortiz; V. A. Joshi; S. Heon; M. Butaney; L. Chen; D. M. Jackman; D. J. Kwiatkowski; N. I. Lindeman; P. A. Janne; B. E. Johnson
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

7517 Background: Systematic genomic testing to identify potential predictive biomarkers to select targeted therapy is emerging for NSCLC. DFCI introduced systematic testing for mutations in BRAF, H...